Comparison of Nebivolol Monotherapy Versus Nebivolol in Combination With Other Antihypertensive Therapies for the Treatment of Hypertension

American Journal of Cardiology

Volumn 103, Issue 2, 2009, Pages 273-278

  Papademetriou, Vasilios ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; DIURETIC AGENT; NEBIVOLOL; PLACEBO; TRIAMTERENE;

AGED; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSOMNIA; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINUSITIS; TREATMENT FAILURE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADMINISTRATION, ORAL; AGED; ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ETHANOLAMINES; EUROPE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PLACEBOS; TREATMENT OUTCOME; UNITED STATES;

EID: 58149471361     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.08.063     Document Type: Article

References (29)

1. Kamp O., Sieswerda G.T., and Visser C.A. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol 92 (2003) 344-348
2. Czuriga I., Riecansky I., Bodnar J., Fulop T., Kruzsicz V., Kristof E., Edes I., and NEBIS Investigators Group. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drugs Ther 17 (2003) 257-263
3. Grassi G., Trevano F.Q., Facchini A., Toutouzas T., Chanu B., and Mancia G. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press Suppl 2 (2003) 35-40
4. Van Nueten L., Lacourciere Y., Vyssoulis G., Korlipara K., Marcadet D.M., Dupont A.G., and Robertson J.I. Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial. Am J Ther 5 (1998) 237-243
5. Van Nueten L., Schelling A., Vertommen C., Dupont A.G., and Robertson J.I. Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomised trial. J Hum Hypertens 11 (1997) 813-819
6. Van Nueten L., Taylor F.R., and Robertson J.I. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens 12 (1998) 135-140
7. Cleophas T.J., Grabowsky I., Niemeyer M.G., Makel W.N., and van der Wall E.E. Long-term efficacy of nebivolol monotherapy in patients with hypertension. Curr Ther Res Clin Exp 62 (2001) 451-461
8. Greathouse M. A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to assess the efficacy and safety of nebivolol in patients with stage I or II hypertension. Clin Cardiol (2008) In press
9. Saunders E., Smith W.B., DeSalvo K.B., and Sullivan W.A. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich) 9 (2007) 866-875
10. Weiss R.J., Weber M.A., Carr A.A., and Sullivan W.A. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich) 9 (2007) 667-676
11. Ambrosioni E., and Borghi C. Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective beta-blockers in the treatment of hypertension: a meta-analysis. High Blood Press Cardiovasc Prev 12 (2005) 27-35
12. Gradman A. Safety and tolerability of nebivolol: a pooled safety analysis comparing typical β-blocker-associated adverse events with placebo. J Clin Hypertens (Greenwich) 10 suppl A (2008) A120
13. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Jones D.W., Materson B.J., Oparil S., Wright Jr. J.T., and Roccella E.J. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
14. Bristow M.R., Nelson P., Minobe W., and Johnson C. Characterization of β1-adrenergic receptor selectivity of nebivolol and various other beta-blockers in human myocardium. Am J Hypertens 18 suppl (2005) 51A-52A
15. Cockcroft J.R., Chowienczyk P.J., Brett S.E., Chen C.P.L.-H., Dupont A.G., van Nueten L., Wooding S.J., and Ritter J.M. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 274 (1995) 1067-1071
16. Tzemos N., Lim P.O., and MacDonald T.M. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind crossover study. Circulation 104 (2001) 511-514
17. Prichard B.N., Cruickshank J.M., and Graham B.R. Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Press 10 (2001) 366-386
18. Wojciechowski B., and Papademetriou V. β-Blockers in the management of hypertension: focus on nebivolol. Expert Cardiovasc Ther 6 (2008) 471-479
19. 1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. Cardiovasc Ther (2008) In press
20. Sarafidis P.A., and Bakris G.L. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM 99 (2006) 431-436
21. Bakris G.L., Fonseca V., Katholi R.E., McGill J.B., Messerli F.H., Phillips R.A., Raskin P., Wright Jr. J.T., Oakes R., Lukas M.A., Anderson K.M., and Bell D.S. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292 (2004) 2227-2236
22. Giugliano D., Acampora R., Marfella R., De Rosa N., Ziccardi P., Ragone R., De Angelis L., and D'Onofrio F. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 126 (1997) 955-959
23. Jacob S., Rett K., Wicklmayr M., Agrawal B., Augustin H.J., and Dietze G.J. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 14 (1996) 489-494
24. Poirier L., Cleroux J., Nadeau A., and Lacourciere Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 19 (2001) 1429-1435
25. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the diagnosis and treatment of hypertension. Endocr Pract 12 (2006) 193-222
26. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., Grassi G., Heagerty A.M., Kjeldsen S.E., Laurent S., et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28 (2007) 1462-1536
27. Amery A., Birkenhager W., Brixko P., Bulpitt C., Clement D., Deruyttere M., De Schaepdryver A., Fagard R., Forette F., Forte J., et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on high blood pressure in the elderly (EWPHE). Postgrad Med J 62 (1986) 919-924
28. Barzilay J.I., Davis B.R., Cutler J.A., Pressel S.L., Whelton P.K., Basile J., Margolis K.L., Ong S.T., Sadler L.S., and Summerson J. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 166 (2006) 2191-2201
29. Grassi G., Seravalle G., Dell'Oro R., Trevano F.Q., Bombelli M., Scopelliti F., Facchini A., and Mancia G. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 21 (2003) 1761-1769